Lake Street Capital Increases LeMaitre Vascular (NASDAQ:LMAT) Price Target to $110.00

LeMaitre Vascular (NASDAQ:LMAT - Free Report) had its target price lifted by Lake Street Capital from $105.00 to $110.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier's stock.

Several other equities analysts have also recently issued reports on LMAT. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday. Finally, StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Trading Up 0.3 %

LMAT traded up $0.31 during midday trading on Friday, hitting $92.16. 299,488 shares of the company were exchanged, compared to its average volume of 137,430. The company's 50 day simple moving average is $96.89 and its 200 day simple moving average is $94.90. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of 50.36, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. On average, equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be paid a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular's payout ratio is 41.24%.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock valued at $1,227,000 after purchasing an additional 4,330 shares during the last quarter. Townsquare Capital LLC grew its holdings in shares of LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock worth $4,454,000 after buying an additional 13,210 shares in the last quarter. Barclays PLC raised its position in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after buying an additional 29,180 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth about $567,000. Finally, Charles Schwab Investment Management Inc. boosted its position in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after acquiring an additional 11,395 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.